Tetraphase Pharmaceuticals, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$798Kgeneral payments (2019-2025)
$0.00research payments (2019-2025)
2,101clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Marya Zilberberg | Leeds, MA | Pulmonary Disease | $98,500.00 |
| Abhay Dhand | Valhalla, NY | Infectious Disease | $60,294.70 |
| Michael Gelfand | Memphis, TN | Infectious Disease | $46,435.44 |
| Andrew Shorr | Washington, DC | Pulmonary Disease | $41,282.75 |
| Joseph Solomkin | Cincinnati, OH | Trauma Surgery | $32,030.04 |
| Tony Hodges | Phoenix, AZ | Pulmonary Disease | $27,046.35 |
| Edward Dominguez | Dallas, TX | Infectious Disease | $26,499.92 |
| Jason Sniffen | Altamonte Springs, FL | Infectious Disease | $25,776.34 |
| Joshua Rosenberg | Brooklyn, NY | Critical Care Medicine (Internal Medicine) | $22,962.56 |
| Arthur Jeng | Sylmar, CA | Infectious Disease | $22,513.45 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.